[Preclinical study of third generation beta 2-stimulant (procaterol) on inhibition of uterine contraction (author's transl)].
A preclinical study was carried out on the beta 2-effect of procaterol, a new third generation beta 2-stimulant, by testing its inhibitory effect on uterine contraction. 1) The inhibitory effect of procaterol on uterine contraction in pregnant rats showed the same pattern as did treatment with second generation beta 2-stimulants (terbutaline, ritodrine). Procaterol showed the inhibitory effect at the lowest dose (0.05 microgram/ml) of the 20 inhibitory substances. 2) As for changes in c-AMP and c-GMP after administering procaterol to rats in the later stage of pregnancy, an increase in c-AMP and a decrease in c-GMP were observed, and the % changes were lower than the second generation beta 2-stimulants (in vitro). Likewise, in the in vivo study, changes in serum c-AMP in pregnant rats showed the same tendency as did the in vitro study. The c-AMP values in uterus, placenta and fetus increased as they did after treatment with ritodrine. Changes in c-GMP, however, showed different results after treatment with ritodrine, and an increase in the uterus and liver was observed but no changes were observed in the placenta and fetus.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D008099:Liver / Q000378:metabolism; D017265:Procaterol; D051381:Rats; D014590:Uterine Contraction / Q000187:drug effects*; D014599:Uterus / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D000242:Cyclic AMP; D006152:Cyclic GMP; D017265:Procaterol